Structural differences between the putative carbohydrate-recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling

被引:5
|
作者
Vergoten, Gerard [1 ]
Zanetta, Jean-Pierre [1 ]
机构
[1] Univ Sci & Tech Lille Flandres Artois, Unite Glycobiol Struct & Fonctionnelle, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France
关键词
cytokine; lectin; oligosaccharide; ganglioside; modeling; signaling;
D O I
10.1007/s10719-006-9021-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In a previous report (Cebo et al. J Biol Chem 276 (2001) 5685-5691), it was established that biologically active recombinant human IL-1 alpha and IL-1 beta had different carbohydrate-binding properties. IL-1 alpha recognized a di-antennary N-glycan with two alpha 2-3-linked sialic acid residues, whereas IL-1 beta recognized the GM(4), a alpha 2-3-linked sialylated glycosphingolipid. These different carbohydrate-binding properties of two interleukins binding to the same receptor (IL-1R) could explain why these molecules had different biological effects and cell specificities. Molecular modeling of the ligands and in silico docking experiments defined putative carbohydrate-recognition domains localized in the same area of the two molecules, a domain different from that defined as the type I IL-1R binding domain. The calculated pattern of hydrogen bonding and of van der Waals interactions fulfilled the essential features observed for calcium-independent lectins (mammalian, viral or bacterial). The analysis of the same domain of the third members of this family of molecules, the IL-1R-antagonist, indicated it did not fulfill the criteria for carbohydrate-recognition domains. It is proposed that its role as a pure antagonist is due to the absence of lectin activity and consequently explained its inability to associate IL-1R with other surface molecular complexes necessary for signaling.
引用
收藏
页码:183 / 193
页数:11
相关论文
共 50 条
  • [1] Structural differences between the putative carbohydrate-recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling
    Gérard Vergoten
    Jean-Pierre Zanetta
    Glycoconjugate Journal, 2007, 24 : 183 - 193
  • [2] Detection of IL-1 alpha, IL-I beta and IL-1 receptor antagonist in blister fluid of bullous pemphigoid
    Schmidt, E
    Mittnacht, A
    Schomig, H
    Dummer, R
    Brocker, EB
    Zillikens, D
    JOURNAL OF DERMATOLOGICAL SCIENCE, 1996, 11 (02) : 142 - 147
  • [3] Interleukin-1α (IL-1α), IL-1β, IL-1 receptor type I, IL-1 receptor antagonist, and TGF-β1 mRNAs in pediatric astrocytomas, ependymomas, and primitive neuroectodermal tumors
    Ilyin, SE
    Gonzalez-Gomez, I
    Gilles, FH
    Plata-Salaman, CR
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1998, 33 (02) : 125 - 137
  • [4] AN IL-1 RECEPTOR AND AN IL-1 RECEPTOR ANTAGONIST ATTENUATE MURAMYL DIPEPTIDE- AND IL-1-INDUCED SLEEP AND FEVER
    IMERI, L
    OPP, MR
    KRUEGER, JM
    AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (04): : R907 - R913
  • [5] THE SYNTHESIS OF IL-1 RECEPTOR ANTAGONIST (IL-1RA) BY SYNOVIAL FIBROBLASTS IS MARKEDLY INCREASED BY THE CYTOKINES TNF-ALPHA AND IL-1
    MARTELPELLETIER, J
    MCCOLLUM, R
    PELLETIER, JP
    BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1175 (03) : 302 - 305
  • [6] SOLUBLE TYPE-II INTERLEUKIN-1 (IL-1) RECEPTOR BINDS AND BLOCKS PROCESSING OF IL-1-BETA PRECURSOR AND LOSES AFFINITY FOR IL-1 RECEPTOR ANTAGONIST
    SYMONS, JA
    YOUNG, PR
    DUFF, GW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) : 1714 - 1718
  • [7] Involvement of IL-6 and IL-1 receptor antagonist on intellectual disability
    Aureli, A.
    Sebastiani, P.
    Del Beato, T.
    Marimpietri, A. E.
    Graziani, A.
    Sechi, E.
    Di Loreto, S.
    IMMUNOLOGY LETTERS, 2014, 162 (01) : 124 - 131
  • [8] INTERLEUKIN-1-BETA (IL-1-BETA), IL-1 RECEPTOR ANTAGONIST, AND TNF-ALPHA PRODUCTION IN WHOLE-BLOOD
    NERAD, JL
    GRIFFITHS, JK
    VANDERMEER, JWM
    ENDRES, S
    POUTSIAKA, DD
    KEUSCH, GT
    BENNISH, M
    SALAM, MA
    DINARELLO, CA
    CANNON, JG
    JOURNAL OF LEUKOCYTE BIOLOGY, 1992, 52 (06) : 687 - 692
  • [9] IL-1 Receptor Accessory Protein-Ig/IL-1 Receptor Type II-Ig Heterodimer Inhibits IL-1 Response More Strongly than Other IL-1 Blocking Biopharmaceutical Agents
    Haruo Hanawa
    Yoshimi Ota
    Limin Ding
    He Chang
    Kaori Yoshida
    Keita Otaki
    Kazuhisa Hao
    Sou Kasahara
    Makoto Kodama
    Mikio Nakazawa
    Yoshifusa Aizawa
    Journal of Clinical Immunology, 2011, 31 : 455 - 464
  • [10] IL-1 Receptor Accessory Protein-Ig/IL-1 Receptor Type II-Ig Heterodimer Inhibits IL-1 Response More Strongly than Other IL-1 Blocking Biopharmaceutical Agents
    Hanawa, Haruo
    Ota, Yoshimi
    Ding, Limin
    Chang, He
    Yoshida, Kaori
    Otaki, Keita
    Hao, Kazuhisa
    Kasahara, Sou
    Kodama, Makoto
    Nakazawa, Mikio
    Aizawa, Yoshifusa
    JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (03) : 455 - 464